Company Filing History:
Years Active: 2021
Title: Claire Gueguen: Innovator in Allergy Immunotherapy
Introduction
Claire Gueguen is a prominent inventor based in Reading, GB. She has made significant contributions to the field of allergy immunotherapy, holding 2 patents that focus on innovative methods for predicting patient responses to treatment.
Latest Patents
Her latest patents include "IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy." This invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy. Another notable patent is "Markers of immune response," which involves methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell. This patent also outlines methods for assessing immune responses in patients undergoing immunotherapy or who have been administered a vaccine.
Career Highlights
Claire Gueguen works at Stallergenes, a company dedicated to developing innovative treatments for allergies. Her work has been instrumental in advancing the understanding of immune responses in allergic patients.
Collaborations
She collaborates with notable colleagues, including Laurent Mascarell and Véronique Bodo, who contribute to her research and development efforts.
Conclusion
Claire Gueguen's work in allergy immunotherapy exemplifies the impact of innovative thinking in medicine. Her patents and collaborations continue to pave the way for advancements in patient care and treatment efficacy.